Last updated on October 13th, 2026 at 09:20 pm
Synthetic opioids, a class of powerful pain medications chemically engineered to mimic the effects of natural opioids like morphine, are a major public health concern. After the opioid crisis of the late ’90s and early 2000s, their destruction lingers on. Their potency, ease of production, and illegal distribution have fueled a surge in overdoses and addiction.
The legal landscape surrounding synthetic opioids is complex and constantly evolving. While some synthetic opioids, like oxycodone and hydrocodone, are available for prescription pain management under strict regulations, others fall under the category of Schedule II controlled substances. This classification indicates a high potential for abuse and dependence, requiring a doctor’s prescription for legitimate use.
However, the illicit market thrives on illegally manufactured synthetic opioids, particularly fentanyl and its analogs. These unregulated variations are often significantly more potent than morphine and pose a substantial overdose risk. Here’s a breakdown of availability:
Carrara founder Richard Taite described where much of that illicit drug supply comes from. In an October 2016 Psychology Today column, he wrote: “Opioids are often manufactured overseas and sold illegally on the streets in the United States.”
While synthetic opioids offer pain relief in medical settings, their misuse carries a multitude of dangers:
The synthetic opioid landscape is vast and constantly evolving. Here are some commonly encountered types:
It’s crucial to remember that this list is not exhaustive. New synthetic opioids are constantly being developed, making it even more important to be aware of the dangers and seek help from qualified professionals if struggling with opioid use disorder.
Remember, help is available, and you don’t have to navigate this alone.
Opioids fall into three broad groups: natural opiates, semi-synthetic opioids, and fully synthetic opioids. All bind to mu-opioid receptors, but potency, duration, and risk profiles vary. Understanding these types clarifies both medical uses and the hazards seen in the illicit market. For a clearer foundation on classifications, compare core distinctions in opioids versus opiates and how each category is defined.
Derived from the opium poppy, morphine and codeine are used for pain and cough suppression. They can cause tolerance and dependence, especially with prolonged or high-dose use. Codeine cough syrups popularized as “Lean” exemplify how medical products can be misused recreationally with serious consequences.
Created by modifying natural opiates, these include heroin and oxycodone. OxyContin’s widespread prescribing set the stage for dependency; as prescriptions tightened, some transitioned to heroin for cost and availability. Semi-synthetics vary in strength, with misuse rapidly escalating tolerance and overdose risk.
Fully synthetic opioids are manufactured without direct poppy derivatives. Methadone is long-acting, used for pain management, and effective for treating opioid use disorder when dispensed and monitored appropriately, but it requires careful dosing to avoid accumulation and respiratory depression.
Pharmacy opioids follow strict manufacturing standards, so dose and purity are consistent. Counterfeit pills, often stamped to mimic brands like Percocet or Xanax, frequently contain fentanyl in unpredictable amounts. This variability drives many unintentional overdoses even among people with prior opioid tolerance.
Clinicians see those unintentional overdoses firsthand. Addiction psychiatrist Dr. Brett Shurman described losing count of the fentanyl-related deaths among his patients in a December 2025 episode of Carrara’s podcast We’re Out of Time: accidental overdoses among people who often did not know they were taking fentanyl at all.
Potency and half-life determine how quickly effects occur and how long they last. Misinformation about duration led some patients to redose too soon. With illicit fentanyl, microgram differences matter, so small measurement errors or a stronger batch can abruptly turn use into a fatal overdose.
Opioids bind to receptors in the brain and spinal cord to block pain and trigger dopamine release, producing euphoria and sedation. Short-term relief can shift into tolerance, dependence, and withdrawal as the nervous system adapts. Respiratory depression is the critical mechanism behind fatal overdoses; understanding how opioids alter neural signaling and affect the brain explains why these risks escalate.
Tablets, powders, or injectables can all produce rapid effects. As tolerance rises, people may increase dose or switch to stronger products like fentanyl.
As regulation curbed pill mills and tightened prescribing, the illicit market filled demand with cheaper, potent synthetics. Fentanyl’s low production cost and high potency made it appealing for traffickers, who pressed counterfeit pills and cut heroin or cocaine, increasing exposure among unsuspecting users.
This transition accelerated around 2015, with fentanyl saturating supplies nationwide. Overdose deaths surged, peaking above 80,000 annually for opioids.
As prescribing tightened, people already dependent on opioids looked elsewhere. Carrara founder Richard Taite described that pressure in an October 2016 Psychology Today column on the DEA’s cut to prescription opioid production: “Those who are already addicted and are unable to get drugs from their physician will be forced to find their drugs wherever they can.”
In the 1970s, a “speedball” referred to a mix of cocaine and heroin. Today, we face a deadlier version: “speedball 2.0”. Fentanyl has transformed every drug it touches into a crisis, amplifying the risks for cocaine users and those who’ve previously used older opioids like heroin.
Opioid addiction involves compulsive use despite harm, driven by neuroadaptations and withdrawal avoidance. Warning signs include early refills, doctor shopping, isolation, nodding, pinpoint pupils, and withdrawal symptoms between doses; recognize early signs of opioid addiction to intervene sooner and reduce harm.
Yes. Naloxone (Narcan) rapidly displaces opioids from receptors to restore breathing if given in time. It is safe, easy to use, and can be administered by bystanders. Prevention focuses on avoiding illicit sources, not using alone, testing substances, and avoiding mixing with sedatives or alcohol; learn where to obtain naloxone and how to use it effectively.
Community access to naloxone and fentanyl test strips reduces deaths. After reversal, medical evaluation is critical because naloxone can wear off before long-acting opioids do. Linking people to treatment immediately after an overdose significantly improves survival and long-term outcomes.
Evidence-based care combines medications for opioid use disorder with counseling and recovery supports. Treatment should be individualized, continuous, and focused on reducing harm and preventing relapse; consider starting evidence-based medications for opioid use disorder that reduce mortality.
Buprenorphine and methadone reduce cravings and withdrawal, lowering overdose risk and improving retention. Extended-release naltrexone blocks opioid effects but requires full detox first. These medications, paired with behavioral therapies, are the gold standard for reducing mortality and supporting recovery.
Medical detox provides supervised stabilization with comfort medications and careful monitoring. While detox alone is not treatment, it is often the first step before initiating buprenorphine or methadone and transitioning into structured therapy to prevent rapid relapse and overdose.
Approaches like cognitive behavioral therapy, motivational interviewing, and contingency management build coping skills, reduce triggers, and improve motivation. Group therapy and family involvement address social dynamics, strengthen accountability, and rebuild supportive networks essential for sustained recovery.
Residential treatment offers 24/7 support, medical oversight, and daily therapy. Effective programs integrate nutrition, exercise, sleep, and mindfulness to repair health. A step-down plan to intensive outpatient or outpatient care sustains progress through therapy, medication management, and recovery coaching.
Relapse risk is highest after detox due to lost tolerance. Ongoing medication, therapy, and a written relapse prevention plan reduce risk. Regular follow-ups, peer support, and crisis planning create safety nets. Skills for managing pain without opioids protect long-term recovery trajectories.
Consider inpatient treatment if you experience severe withdrawal, repeated overdose, polysubstance use, unstable housing, or co-occurring mental health conditions. Inpatient programs provide medical detox, start medications, and deliver intensive therapy in a structured, recovery-focused environment; understand when inpatient rehab for opioids offers the safest path to stabilization.
Sources
Dr. Kenneth Spielvogel is a board-certified physician with nearly 30 years of clinical experience and a specialized focus on addiction medicine, metabolic health, hormonal optimization, and long-term recovery. As Senior Medical Officer at Carrara Treatment Wellness & Spa, he helps lead a physician-driven approach to recovery that integrates medical, psychological, and lifestyle interventions to support lasting healing.
A graduate of the George Washington University School of Medicine and residency-trained at the University of Colorado Health Sciences Center, Dr. Spielvogel is board-certified in Obstetrics and Gynecology. Throughout his distinguished career, he has cared for thousands of patients in areas including women’s health, hormone replacement therapy, fertility, prenatal care, minimally invasive surgery, and preventive medicine.
Witnessing the devastating impact of substance use disorders on patients and families inspired Dr. Spielvogel to expand his focus into addiction medicine. He has since dedicated years of continuing education and clinical practice to the treatment of substance use disorders, integrating evidence-based addiction care into both inpatient and outpatient settings.
Today, Dr. Spielvogel is particularly interested in the intersection of addiction medicine, metabolic health, and recovery. His work explores the role of GLP-1 therapies, hormonal health, exercise physiology, body composition, and biomarker-driven care in reducing cravings, improving overall health, and supporting sustainable recovery outcomes.
Known for his compassionate, patient-centered approach, Dr. Spielvogel believes in building strong relationships with those he serves, helping individuals make informed decisions about their health and recovery. Fluent in Spanish, he is committed to delivering culturally competent care to diverse patient populations.
Credentials: MD, FACOG. California Physician and Surgeon license C55705 (Medical Board of California). Board certified in Obstetrics and Gynecology (American Board of Obstetrics and Gynecology). Member, American College of Obstetricians and Gynecologists. Clinical faculty, UC Irvine Department of Obstetrics and Gynecology, since 2016. NPI 1235104605.